科学家开发了一种新的生物反应方法,用于大规模生产肺类组织,用于个人化疾病研究和药物测试。 Scientists developed a new bioreactor method to mass-produce lung organoids for personalized disease research and drug testing.

Duisburg-Essen大学的科学家,由Diana Klein教授领导,发明了一种可扩缩的自动化方法,用于利用生物反应器生产肺部有机体,推进个性化肺病研究。 Scientists at the University of Duisburg-Essen, led by Professor Diana Klein, have created a scalable, automated method for producing lung organoids using a bioreactor, advancing personalized lung disease research. 这些实验室培育的组织模型来自干细胞,比传统文化更能模仿人类肺部结构,可以进行高通量药物检测和个别化治疗预测。 These lab-grown tissue models, derived from stem cells, mimic human lung structure better than traditional cultures and may enable high-throughput drug testing and individualized therapy prediction. 虽然生物反应器培养的器官在细胞组成上略有不同,但它们提供了更有效,更少劳动密集的手工方法替代方案,并减少了对动物试验的依赖. While bioreactor-grown organoids differ slightly in cell composition—showing fewer alveolar spheres—they offer a more efficient, less labor-intensive alternative to manual methods and reduce reliance on animal testing. 该技术发表在《生物工程和生物技术前沿》上,有望通过个性化测试改善癌症治疗结果,尽管还需要进一步优化生物反应器设计和生长条件。 The technique, published in Frontiers in Bioengineering and Biotechnology, holds promise for improving cancer treatment outcomes through personalized testing, though further optimization of bioreactor design and growth conditions is needed.